Generics Bulletin is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic User Fee Hikes Could Disrupt US FDA Drug Pricing Campaign

Executive Summary

New GDUFA program fee is high enough that sponsors may withdraw applications to reduce their fee exposure, agency estimates.


Related Content

FDA's Generic Approvals Catch A Bit Of Breath In July But Continue At Fast Pace
FDA Drug Pricing Policy Offers Short-Term PR Gain, More Long-Term Actual Benefit
Generic Industry Consolidating But Still Mysterious
Gottlieb Places Drug Pricing Out Front In First Speech To US FDA Staff
Generic Drug Puzzle: Why Did ANDA Submissions Spike Again?
ANDA Holder Fee Will Start With Industry-Driven Database 'Clean-Up'
Generic Drug User Fees Will Jump More Than 50% In FY 2018
GDUFA: Fee Avoidance Affects Rates Again
Generic User Fees Need Small Business Waiver, Firms Say; Congress May Agree
GDUFA Facility Fees Will Be Significantly Higher Than Expected





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts